Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries
LAUSANNE, Switzerland, June 23 /PRNewswire/ -- Debiopharm Group
(Debiopharm), a Swiss-based global biopharmaceutical group of companies with
a focus on the development of prescription drugs that target unmet medical
needs, announced that Salvacyl(R) (also known under the trade names Moapar(R)
Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug
Technology Intended to Improve Outcome of Intrauterine Insemination and In Vitro Fertilization Procedures
LA JOLLA, Calif., June 22 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has entered into an agreement with Clinical Trials International...
New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring
IRVINE, Calif., June 12 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI ), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that three new independent studies demonstrating the clinical accuracy and utility of Masimo PVI as a nonin...
Clinical Trial Results of Pollogen's TriPollar(TM) Radio Frequency Technology published in the Journal of the European Academy of Dermatology and Venereology
TEL AVIV, Israel, June 2 /PRNewswire/ -- Clinical trial results using the
regen(TM) system, the newest aesthetic solution powered by 3rd generation
TriPollar RF technology on cellulite treatment and body contouring, have been
published in the online Journal of the European
Academy of Dermatolo...
Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
PARIS, May 18 /PRNewswire/ -- Novexel, a speciality pharmaceutical
company focused on the discovery and development of novel antibiotics
designed to overcome the significant global problem of microbial resistance,
announces that its two most advanced pipeline products NXL104 and NXL103 are
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Study Results Demonstrated Significant Weight Loss in Obese Patients Treated with Qnexa
MOUNTAIN VIEW, Calif., May 7 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS ), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today ann...
Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
Clinical results and advantage over linezolid in resistance acquisition by Staph aureus among data to be presented at infectious disease meeting
SAN DIEGO, Calif., May 6 /PRNewswire/ -- Trius Therapeutics, Inc., a biopharmaceutical company developing best-in-class drugs for the treatment of s...
Ironwood Announces Linaclotide European Licensing Agreement with Almirall
- Ironwood Will Receive Up To $55 Million in Near Term Payments -
CAMBRIDGE, Mass., May 4 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced that the company has entered into an out-licensing agreement with Laboratorios Almirall, S.A. for European
rights to develop and commerciali...
Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
Unique GeneXpert(R) System Capabilities Enable Powerful New TB Diagnostic Tool
SUNNYVALE, Calif., April 27 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today announced the release of Xpert(R) MTB/RIF as a CE IVD Mark product under the European
Directive on In Vitro Diagnostic Medical...
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Final results from three large PEGINTRON(TM) clinical studies address key questions in the treatment of hepatitis C
COPENHAGEN, Denmark, April 27 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today reported that final results of three large PEGINTRON(TM) (peginterferon ...
InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
- Results inform selection of doses, regimens to be explored in Phase 2b study -
-- Phase 2b program anticipated to begin in summer 2009 --
COPENHAGEN , April 24 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that results from a 14-day Phase 1b clinical stu...
Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients
Sustained Benefits for Patients Awaiting Transplantation
ANN ARBOR, Mich., April 7 /PRNewswire/ -- The DuraHeart(TM) Left Ventricular Assist System (LVAS) shows sustained benefits in providing safe and reliable long-term circulatory support with an improved survival rate and an acceptable adv...
Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
DUBLIN, March 16 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ:
SHPGY ), the global specialty biopharmaceutical company, announces that it has
decided to withdraw the European
Marketing Authorization Application (MAA)
for DAYTRANA(TM) (methylphenidate transdermal system) for the trea...
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
MISSISSAUGA, ON, March 13 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Alternext US:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported that its poster entitled, "Binding properties of the ant...
Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
THE WOODLANDS, Texas, March 5 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Dr. Philip Brown , senior vice president of clinical develop...
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
SEATTLE, Feb. 10 /PRNewswire-FirstCall/ -- Cell Therapeutics (CTI) (NASDAQ and MTA: CTIC) today announced that they have executed a definitive collaborative agreement with IDIS to manage its investigational drug pixantrone on a named patient basis in Europe. Pixantrone will be supplied by IDIS to...
Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
First and Only Approved Platelet Producer in Europe Represents New Treatment Approach for Serious Chronic Autoimmune Disorder
ZUG, Switzerland, Feb. 6 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN ) today announced that the European
Commission (EC) has granted marketing authorisation for Np...
EpiDerm's Skin Irritation Test Fully Validated in European Union
Significant milestone met in development and validation of non-animal alternative test methods
ASHLAND, Mass., Dec. 17 /PRNewswire/ -- MatTek Corporation today announced that the ECVAM Scientific Advisory Committee (ESAC) endorsed the scientific validity of the Modified EpiDerm Skin Irrit...
CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
Schering-Plough Receives CHMP Positive Opinion for TEMODAL(R) Intravenous Formulation and Oral TEMODAL Sachet Presentation -- Providing Potential New Treatment Options for EU Patients with Certain Primary Brain Tumors
KENILWORTH, N.J., Dec. 8 /PRNewswire-FirstCall/ -- Schering-Plough Corp...
Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
COLLEGEVILLE, Pa., Dec. 3 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals,
a division of Wyeth (NYSE: WYE ), announced today that it has submitted a
marketing authorization application (MAA) to the European
(EMEA) for approval to market its investigational 13-valent pneumococcal...
Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
THOUSAND OAKS, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Amgen
(Nasdaq: AMGN ) today announced that the European
Committee for Medicinal
Products for Human Use (CHMP) has issued a positive opinion recommending
marketing authorisation for Nplate(TM) (romiplostim) in the European
(EU). The ...
Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
- Milestone Marks the First Time a European
Patient with Active Celiac
Disease has Enrolled in a Clinical Trial for an Investigational Medication from Alba Therapeutics -
BALTIMORE, Nov. 11 /PRNewswire/ -- Alba Therapeutics Corporation
announced today that for the firs...
Inhaled Nitric Oxide Data Presented at European Academy of Pediatrics Meeting
CLINTON, N.J., Oct. 25 /PRNewswire/ -- Ikaria Holdings, Inc. today
announced that results from its Phase III clinical trial -- INOT27, nitric
oxide for inhalation for the treatment of bronchopulmonary disease (BPD) in
premature babies -- were presented at the European
Academy of Pediatrics in
Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
Non-surgical intervention cures 96% of patients with advanced esophagus condition
SUNNYVALE, Calif., Oct. 19 /PRNewswire/ -- BARRX Medical, Inc. today
announced clinical trial results presented at the United European
Gastroenterology Week (UEGW) in Vienna, Austria...
NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium
TOKYO and CHIPPENHAM, England, October 7 /PRNewswire-FirstCall/ --
Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) and Vectura
Group plc ("Vectura"; LSE: VEC), announce results of two Phase II studies
evaluating the efficacy, safety and tolerability of NVA237 presented at the
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
IRVINE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
(Nasdaq: IDMI ) today announced that it met with representatives of the
Committee for Medicinal Products for Human Use (CHMP) and Secretariat of
Medicines Agency (EMEA) on September 25th, following the
Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
EMERYVILLE, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Neurobiological
Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) today announced that previously
found excess symptomatic intracranial hemorrhage in an earlier European
trial of ancrod (now Viprinex(TM)) for the treatment of acute ischemic
First European Patients Treated With the Percutaneous MitraClip(R) System European
Physicians Show Strong Interest in MitraClip System
MENLO PARK, Calif., Sept. 23 /PRNewswire/ -- Evalve, Inc., the leader
in the development of devices for the percutaneous repair of cardiac
valves, announced today that the first two patients have been treated with
Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
First product launch following acquisition of Organon BioSciences
KENILWORTH, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP ) today announced that the European
BRIDION(R) (sugammadex) injection has begun with its introduction this week
Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008
Results Demonstrate Safety and Efficacy of First-in-Class Neurally Acting Anti-Migraine Agent (NAAMA) for the Treatment of Acute Migraine
LONDON, Sept. 6 /PRNewswire/ -- CoLucid Pharmaceuticals, Inc., an
innovative biotechnology company focusing on therapies for central nervous
Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
Updated Survival Data for Ipilimumab to be Presented
PRINCETON, N.J., Sept. 4 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX ) announced today that nine clinical abstracts for ipilimumab,
an investigational anti-CTLA-4 antibody, in melanoma are scheduled to be
the subject of ...
Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
Comprehensive Data Provide Initial Proof of Concept Across Multiple Applications in the Hospital Setting Poster Presentation Number: 2032 Presenting Author: Dr. Mark Chan
MUNICH, Germany, Sept. 2 /PRNewswire/ -- Regado Biosciences, Inc.
TRANSCEND(TM) Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
Landmark ARB trial investigated Micardis(R) (telmisartan) against placebo
in reducing the composite endpoint of cardiovascular death, myocardial
infarction, stroke and hospitalization for congestive heart failure in ACE
inhibitor intolerant high-risk patients receiving current standard of ca...
Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008
Company to present data from landmark SYNTAX clinical trial
NATICK, Mass., Aug. 26 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX ) today announced the schedule of the Company's major
events and press announcements at the European
Society of Cardiology
Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
Potential for data analysis early 2009
SEATTLE, Aug. 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.'s
(CTI) (Nasdaq: CTIC ; MTA) subsidiary Systems Medicine (SM) announced today
that planned enrollment is complete in the European
Research and Treatment ...
BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
BRIDION allows anesthesiologists to rapidly reverse both moderate and deep levels of muscle relaxation
First product approval from the Schering-Plough combination with Organon BioSciences
KENILWORTH, N.J., July 29 /PRNewswire-FirstCall/ -- Sch...
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
- Company continues to anticipate CHMP opinion in the third quarter;
L-MTP-PE on track for final European
Commission decision in the fourth quarter
IRVINE, Calif., July 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
(Nasdaq: IDMI ) today announced that the CH...
Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
SEATTLE, June 16 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc.
(Nasdaq: TRBN ) today announced presentation of data at the 2008 Annual
European Congress of Rheumatology meeting in Paris demonstrating that
repeat administration with TRU-015, Trubion's lead candidate for the
Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
Data from Phase 1 Single Agent and Phase 1b Combination Clinical Trials Demonstrate Voreloxin's Anti-Leukemic Activity
SOUTH SAN FRANCISCO, Calif., June 16 /PRNewswire-FirstCall/ -- Sunesis
Pharmaceuticals, Inc. (Nasdaq: SNSS ) presented data Saturday from two
clinical trials of t...
XTENT Announces European Regulatory Update
MENLO PARK, Calif., June 12 /PRNewswire-FirstCall/ -- XTENT, Inc.
(Nasdaq: XTNT ) today announced a progress update regarding its application
to the designated European
Notified Body for CE Mark approval of its Custom
NX(R) DES System. XTENT's European
Notified Body confirmed that recently